Edith A. Perez

12.4k total citations · 2 hit papers
87 papers, 4.6k citations indexed

About

Edith A. Perez is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Edith A. Perez has authored 87 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Oncology, 38 papers in Radiology, Nuclear Medicine and Imaging and 22 papers in Cancer Research. Recurrent topics in Edith A. Perez's work include HER2/EGFR in Cancer Research (63 papers), Monoclonal and Polyclonal Antibodies Research (35 papers) and Cancer Treatment and Pharmacology (30 papers). Edith A. Perez is often cited by papers focused on HER2/EGFR in Cancer Research (63 papers), Monoclonal and Polyclonal Antibodies Research (35 papers) and Cancer Treatment and Pharmacology (30 papers). Edith A. Perez collaborates with scholars based in United States, Spain and Italy. Edith A. Perez's co-authors include Luca Gianni, Mark X. Sliwkowski, C. Kent Osborne, Carlos L. Arteaga, Fabio Puglisi, Richard J. Rodeheffer, Alvaro Moreno‐Aspitia, Nancy E. Davidson, Peter A. Kaufman and Silvana Martino and has published in prestigious journals such as Journal of Clinical Oncology, Nature Cell Biology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Edith A. Perez

87 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of HER2-positive breast cancer: current status and future perspectives

2011 696 citations Carlos L. Arteaga, Mark X. Sliwkowski et al. Nature Reviews Clinical Oncology profile →
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

2011 539 citations Edith A. Perez, Nancy E. Davidson et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Edith A. Perez

Since Specialization

Citations

This map shows the geographic impact of Edith A. Perez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edith A. Perez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edith A. Perez more than expected).

Fields of papers citing papers by Edith A. Perez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edith A. Perez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edith A. Perez. The network helps show where Edith A. Perez may publish in the future.

Co-authorship network of co-authors of Edith A. Perez

This figure shows the co-authorship network connecting the top 25 collaborators of Edith A. Perez. A scholar is included among the top collaborators of Edith A. Perez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edith A. Perez. Edith A. Perez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd). 2024 ·Journal of Clinical Oncology ·Mark D. Pegram, Carmen Calfa, Christopher S. Chen, Alfonso Cortés, Arielle L. Heeke, Irene Kang, Barbara Pistilli, Paula R. Pohlmann, Hope S. Rugo, Cristina Saura, Cécile Vicier, Cecelia I. Pearson, Milan Mangeshkar, (unknown), Michael N. Alonso, Dawn Colburn, Edith A. Perez, Joshua Z. Drago	1
2	Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines 2016 ·Journal of Clinical Oncology ·Mithun Vinod Shah, Anne E. Wiktor, Reid G. Meyer, Kathleen Tenner, Karla V. Ballman, Stefan J. Green, William R. Sukov, Rhett P. Ketterling, Edith A. Perez, Robert B. Jenkins	66
3	Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain 2016 ·Cancer Research ·Keith L. Knutson, Raphael Clynes, Barath Shreeder, Patrick Yeramian, (unknown), Karla V. Ballman, Kathleen Tenner, Courtney L. Erskine, Nadine Norton, Donald W. Northfelt, Winston Tan, Carmen Calfa, Mark D. Pegram, Elizabeth A. Mittendorf, Edith A. Perez	47
4	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831 2015 ·Breast Cancer Research ·Edith A. Perez, Frederick L. Baehner, Steven M. Butler, E. Aubrey Thompson, Amylou C. Dueck, Farid Jamshidian, Diana B. Cherbavaz, Carl Yoshizawa, Steven Shak, Peter A. Kaufman, Nancy E. Davidson, Julie R. Gralow, Yan W. Asmann, Karla V. Ballman	17
5	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline 2014 ·Journal of Clinical Oncology ·Naren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, Jennie R. Crews, Nancy E. Davidson, Francisco J. Esteva, Sharon H. Giordano, Ana M. González-Angulo, Jeffrey J. Kirshner, Ian E. Krop, (unknown), Shanu Modi, Debra A. Patt, Edith A. Perez, Jane Perlmutter, Eric P. Winer, Nancy U. Lin	134
6	Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 2013 ·Clinical Cancer Research ·Amylou C. Dueck, Monica M. Reinholz, Xochiquetzal J. Geiger, Kathleen Tenner, Karla V. Ballman, Robert B. Jenkins, Darren Riehle, Beiyun Chen, Ann E. McCullough, Nancy E. Davidson, Silvana Martino, George W. Sledge, Peter A. Kaufman, Leila A. Kutteh, Julie R. Gralow, Lyndsay N. Harris, James N. Ingle, Wilma L. Lingle, Edith A. Perez	19
7	Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer 2013 ·Journal of Clinical Oncology ·Sara A. Hurvitz, Luc Dirix, Judit Kocsis, Giulia Bianchi, Janice Lu, J. Vinholes, Ellie Guardino, Chunyan Song, Barbara Tong, Vivian Ng, Yu-Waye Chu, Edith A. Perez	302
8	Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial 2013 ·Journal of Clinical Oncology ·Edith A. Perez, Amylou C. Dueck, Ann E. McCullough, Beiyun Chen, Xochiquetzal J. Geiger, Robert B. Jenkins, Wilma L. Lingle, Nancy E. Davidson, Silvana Martino, Peter A. Kaufman, Leila A. Kutteh, George W. Sledge, Lyndsay N. Harris, Julie R. Gralow, Monica M. Reinholz	89
9	New frontiers and treatment paradigms for metastatic breast cancer. A Review of an adjunct symposium of the 2011 American Society of Clinical Oncology Annual Meeting, June 4, 2011 Chicago, Illinois. 2011 ·PubMed ·Edith A. Perez, Susan L. Mooberry, Christopher Twelves, Hope S. Rugo	3
10	Treatment of HER2-positive breast cancer: current status and future perspectives breakdown → 2011 ·Nature Reviews Clinical Oncology ·Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne, Edith A. Perez, Fabio Puglisi, Luca Gianni	696
11	Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria 2011 ·JNCI Journal of the National Cancer Institute ·Edith A. Perez, Amylou C. Dueck, Ann E. McCullough, Monica M. Reinholz, Kathleen Tenner, Nancy E. Davidson, Julie R. Gralow, Lyndsay N. Harris, Leila A. Kutteh, David W. Hillman, Robert B. Jenkins, Beiyun Chen	57
12	Current and emerging targeted therapies for metastatic breast cancer 2011 ·Cancer ·Edith A. Perez, Jean‐Philippe Spano	39
13	Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer 2010 ·Clinical journal of oncology nursing ·Frances M. Palmieri, (unknown), Edith A. Perez	2
14	Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2–Positive Breast Cancer 2009 ·The Oncologist ·Vivek Roy, Edith A. Perez	65
15	Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer 2009 ·Human Pathology ·Sejal Shah, Rhett P. Ketterling, Matthew P. Goetz, James N. Ingle, Carol Reynolds, Edith A. Perez, Beiyun Chen	30
16	Does Zinc Sulfate Prevent Therapy-Induced Taste Alterations in Head and Neck Cancer Patients? Results of Phase III Double-Blind, Placebo-Controlled Trial from the North Central Cancer Treatment Group (N01C4) 2007 ·International Journal of Radiation OncologyBiologyPhysics ·Michele Y. Halyard, Aminah Jatoi, Jeff A. Sloan, James D. Bearden, Sujay A. Vora, Philip J. Atherton, Edith A. Perez, (unknown), (unknown), Angela Zhu, Philip J. Stella, Charles L. Loprinzi	85
17	HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations 2006 ·Journal of the National Comprehensive Cancer Network ·Robert W. Carlson, Susan J. Moench, M. Elizabeth H. Hammond, Edith A. Perez, Harold J. Burstein, D. Craig Allred, Charles L. Vogel, Lori J. Goldstein, George Somlo, William J. Gradishar, Clifford A. Hudis, Mohammad Jahanzeb, Azadeh Stark, Antonio C. Wolff, Michael F. Press, Eric P. Winer, Soonmyung Paik, Britt‐Marie Ljung, (unknown)	150
18	Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast Cancer 2006 ·The Oncologist ·José Baselga, Edith A. Perez, Tadeusz Pieńkowski, Richard H. Bell	166
19	High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically 1998 ·Cancer Chemotherapy and Pharmacology ·Primo N. Lara, David R. Gandara, Gregory T. Wurz, Derick Lau, Margaret Uhrich, (unknown), James Raschko, Martin J. Edelman, Timothy W. Synold, (unknown), Franco M. Muggia, Edith A. Perez, (unknown)	8
20	Radiation Recall Dermatitis Induced by Edatrexate in a Patient with Breast Cancer 1995 ·Cancer Investigation ·Edith A. Perez, David L. Campbell, Janice Ryu	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact